This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Consensus Statement on Depression, Anxiety, and Oncology

James C. Ballenger, MD; Jonathan R. T. Davidson, MD; Yves Lecrubier, MD; and David J. Nutt, MD, PhD (International Consensus Group on Depression and Anxiety); and Richard D. Jones, MD; and Ray M. F. Berard, MD

Published: July 1, 2001

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Cancer patients are vulnerable to depression and anxiety for many reasons: metabolic or endocrine alterations, treatment with debilitating chemotherapy regimens, immune response modifiers, and chronic pain associated with their physical illness. Quite apart from the normal emotional impact of the diagnosis of a life-threatening illness, an estimated 20% to 25% of cancer patients meet diagnostic criteria for major depression or anxiety, treatable psychiatric conditions that have serious detrimental effects on their quality of life.1


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Comorbidity , Medical

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...